Lead Product(s) : Suvecaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial for TGCT Treatment
Details : JZP385 (suvecaltamide) is an investigational, highly selective and state-dependent modulator of T-type calcium channels, being evaluated in adult patients with moderate to severe essential tremor.
Brand Name : JZP385
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2024
Lead Product(s) : Suvecaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?